Murine and human in vivo penclomedine metabolism

Clinical Cancer Research

Volumn 2, Issue 6, 1996, Pages 953-962

  Hartman, Neil R ^a,c   O'Reilly, Seamus ^b   Rowinsky, Eric K ^b   Collins, Jerry M ^a   Strong, John M ^a  

^a Ctr for Drug Eval and Research   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENCLOMEDINE;

ANIMAL CELL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBON RADIOISOTOPES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; PICOLINES; PROTEIN BINDING; TISSUE DISTRIBUTION;

EID: 0030014273     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. O'Reilly, S., Grochow, L., Donehower, R. C. Bowling, K., Chen, T. Y., Sartorius, S., Roskes, E., Ludeman, S., Hartman, N. R., Strong, J. M., Struck, R., and Rowinsky, E. K. Phase I and pharmacologic studies of penclomedine, a novel alkylating agent with prominent preclinical activity in breast cancer. Proc. Am. Soc. Clin. Oncol., 14, 471, 1995.
2. Berlin, J., Stewart, J., Tutsch, K., Storer, B., Azoomanian, R., Alberti, D., Feierabend, C., and Wilding, G. Phase I and pharmacokinetic trial of penclomedine (NSC 338720) Proc. Am Assoc. Cancer Res., 36: 238, 1995.
3. Plowman, J., Harrison S. D. Jr., Dykes D. J., Paull, K. D., Narayanan, V., Tobol, H. K., and Griswold, D. P., Jr. Preclinical antitumor activity of an α-picoline derivative, penclomedine (NSC 338720), on human and murine tumors. Cancer Res, 49: 1909-1915, 1989.
4. Harrison, S. D., Jr., Plowman, J., Dykes, D. J., Waud, W. R., and Griswold, D. P., Jr. Preclinical antitumor activity of penclomedine in mice: cross-resistance, schedule dependence, and oral activity against tumor xenografts in brain. Cancer Res., 57: 1979-1983, 1991.
5. Reid, J. M., Mathiesen, D. A., Benson, L. M., Kuffel, M. J., and Ames, M M. Murine pharmacokinetics and metabolism of penclomedine [3,5-dichloro-2,4-dimethyl-6-(trichloromethyl)pyridine, NSC 338720]. Cancer Res., 52: 2830-2834, 1992.
6. Hartman, N. R., Strong, J. M., and Collins, J. M. Metabolism of penclomedine by human liver preparations. Proc. Am. Assoc. Cancer Res., 35: 402, 1994.
7. Hartman, N. R., O'Reilly, S., Rowinsky E. K., Collins, J. M., and Strong, J. M. The in vivo metabolism of penclomedine. Proc. Am. Assoc. Cancer Res., 36: 389, 1995.
8. 14C-penclomedine in rats. Clin. Cancer Res., 2:, 541-548, 1996.